Skip to main content

Advertisement

Volume 3 Supplement 1

ESICM LIVES 2015

Long-Term Follow-Up of Sepsis Induced Immunoparalysis

Article metrics

  • 441 Accesses

Introduction

Severe sepsis induces a state of immunoparalysis.[1] Animal models have demonstrated this to be secondary to microbial-induced host epigenetic alterations, which persist and are associated with long-term immunoparalysis.[2] Whilst human sepsis is associated with poor long-term outcomes in conjunction with recurrent infections,[3] it is not clear if the immunoparalysed state persists following recovery from the initial septic insult.

Objectives

1. To confirm the presence of circulating mediators capable of causing immunoparalysis following bacteraemia.

2. To assess for the presence of immunosuppressive mediators following hospital discharge with full functional recovery.

Methods

Consecutive adult patients (n = 7) with bacteraemia and an admission diagnosis of infection were recruited. Serum was collected at 3 time points; within 48 hours of the positive blood culture, 5 days later & 12 months following hospital discharge. Peripheral blood mononuclear cells (PBMCs) were collected from a healthy control cohort (n = 7) and pooled. Healthy PBMCs were co-cultured with 30% septic serum for 20 hours with and without GM-CSF (200ng/ml). CD14+HLA-DR (mHLA-DR) geometric-mean fluorescent intensity (MFI) was determined using flow cytometry. Data were analysed with non-parametric statistics with results presented as median & IQR .

Results

Three patients required ICU care & four were managed on the ward. Demographic & clinical data are presented in Figure 2. mHLA-DR levels were lower when PBMCs were co-cultured with the baseline bacteraemic sample in comparison with control group serum (Figure 1, P = 0.01). mHLA-DR levels following co-culture with the baseline sample were not significantly different to the levels observed when co-cultured with day 5 serum (Figure 1A). in comparison to the baseline sample, when co-cultured with serum from 12 months, mHLA-DR levels were increased (Figure 1A, P = 0.007). mHLA-DR levels at 12 months were not different from those seen when control serum was used (Figure 1A P = 0.85). mHLA-DR levels were higher in the presence of GM-CSF when co-cultured with baseline (Figure 1B, P = 0.01) and 12 month (Figure 1B, P = 0.02) samples but not with day 5 serum (Figure 1B, P = 0.17).

figure1

Figure 1

Figure 2
figure2

Demographic and clinical details of patients requiring ICU care (severe sepsis) and those receiving ward based care (no organ impairment).

Conclusions

Circulating mediators present in the serum of bacteraemic patients reduces the ability of healthy monocytes to express cell surface HLA-DR, which is reversible in the presence of an immunostimulant. Serum from patients following full recovery from the acute illness does not reduce HLA-DR expression on healthy monocytes.

Grant Acknowledgment

ESICM Basic Science Award 2014.

References

  1. 1.

    Deng JC, et al: Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest. 2006, 116: 2532-42.

  2. 2.

    Carson WF, et al: Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics. 2011, 6: 273-83. 10.4161/epi.6.3.14017.

  3. 3.

    Czaja AS, et al: Readmission and late mortality after paediatric severe sepsis. Paediatrics. 2009, 123: 849-10.1542/peds.2008-0856.

Download references

Author information

Correspondence to M Raja.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Consecutive Adult Patient
  • Follow Hospital Discharge
  • Grant Acknowledgment
  • Express Cell Surface
  • Bacteraemic Patient